Miniatura

Fitxers

SalazarR.pdf (723 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-12-27

Llicència de publicació

cc by (c) Salazar Soler et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173783

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s12885-020-07661-z

Resum

Background: Preoperative chemoradiotherapy with capecitabine is considered as a standard of care for locally advanced rectal cancer. The “Tratamiento de Tumores Digestivos” group (TTD) previously reported in a randomized Ph II study that the addition of Bevacizumab to capecitabine-RT conferred no differences in the pre-defined efficacy endpoint (pathological complete response). We present the follow-up results of progression-free survival, distant relapse-free survival, and overall survival data at 3 and 5 years. Methods: Patients (pts) were randomized to receive 5 weeks of radiotherapy (45 Gy/25 fractions) with concurrent Capecitabine 825 mg/m2 twice daily, 5 days per week with (arm A) or without (arm b) bevacizumab (5 mg/kg once every 2 weeks). Results: In our study, the addition of bevacizumab to capecitabine and radiotherapy in the neoadjuvant setting shows no differences in pathological complete response (15.9% vs 10.9%), distant relapse-free survival (81.0 vs 80.4 and 76.2% vs 78.2% at 3 and 5 years respectively), disease-free survival (75% vs 71.7 and 68.1% vs 69.57% at 3 and 5 years respectively) nor overall survival at 5-years of follow-up (81.8% vs 86.9%). Conclusions: the addition of bevacizumab to capecitabine plus radiotherapy does not confer statistically significant advantages neither in distant relapse-free survival nor in disease-free survival nor in Overall Survival in the short or long term.

Matèries

Càncer colorectal, Quimioteràpia, Radioteràpia

Matèries (anglès)

Chemotherapy, Radiotherapy

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SALAZAR SOLER, Ramón, CAPDEVILA, Jaume, MANZANO, José luis, PERICAY, Carles, MARTÍNEZ VILLACAMPA, Mercedes, LÓPEZ, Carlos, LOSA, Ferrán, SAFONT, María josé, GÓMEZ ESPANA, Auxiliadora, ALONSO ORDUÑA, Vicente, ESCUDERO, Pilar, GALLEGO, Javier, GARCÍA PAREDES, Beatriz, PALACIOS, Amalia, BIONDO, Sebastián, GRÁVALOS, Cristina, ARANDA, Enrique, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. _BMC Cancer_. 2020. Vol. 20. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/173783]

Exportar metadades

JSON - METS

Compartir registre